Novo Nordisk offering its GLP-1 drug Wegovy at huge discount
Novo Nordisk (NVO) is now offering its GLP-1 weight-loss drug Wegovy at half its price, amounting to $499 per month. Catalysts co-hosts Seana Smith and Madison Mills report on the latest news surrounding the pharmaceutical giant's position in the obesity drug space.
Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
24/7 Wall St. on MSN13d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...
“We’re using the years of successful growth to invest in that capacity,” he added. Novo Nordisk’s GLP-1 drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback